© Springer-Verlag Berlin Heidelberg 2017Sun-Whe Kim and Hiroki Yamaue (eds.)Pancreatic Cancer10.1007/978-3-662-47181-4_14 14. The History and Evolution of Pancreaticoduodenectomy James F. Griffin1 and Christopher L. Wolfgang1 (1) Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA …
© Springer-Verlag Berlin Heidelberg 2017Sun-Whe Kim and Hiroki Yamaue (eds.)Pancreatic Cancer10.1007/978-3-662-47181-4_13 13. Guideline for the Management of Pancreatic Neuroendocrine Tumor Gabriele Spoletini1, Domenico Tamburrino1, Francesca Muffatti2, Stefano Crippa2, Valentina Andreasi2, Stefano Partelli2 and Massimo Falconi2 (1) HPB and Liver Transplant Surgery, Royal…
TNM classification (UICC/AJCC 7th edition) Primary tumor (T) TX Primary tumor cannot be assessed T0 No evidence of primary tumor Tis Carcinoma in situ (including lesions classified as PanIn III)…
© Springer-Verlag Berlin Heidelberg 2017Sun-Whe Kim and Hiroki Yamaue (eds.)Pancreatic Cancer10.1007/978-3-662-47181-4_2 2. Molecular Alterations in Pancreatic Cancer Toru Furukawa1 (1) Institute for Integrated Medical Sciences, Tokyo Women’s Medical University, Tokyo, Japan Toru Furukawa Email: furukawa.toru@twmu.ac.jp…
© Springer-Verlag Berlin Heidelberg 2017Sun-Whe Kim and Hiroki Yamaue (eds.)Pancreatic Cancer10.1007/978-3-662-47181-4_6 6. Tumor Markers Ji Kon Ryu1 (1) Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea …
Adenocarcinoma 8140/3 Lepidic adenocarcinoma 8250/3 Acinar adenocarcinoma 8551/3 Papillary adenocarcinoma 8260/3 Micropapillary adenocarcinoma 8265/3 Solid adenocarcinoma 8230/3 Invasive mucinous adenocarcinoma 8253/3 Mixed invasive mucinous and non-mucinous adenocarcinoma 8254/3 Colloid adenocarcinoma…
Fig. 3.1 18F-FDG-PET (transaxial section) showed increased uptake of tracers in a primary tumor of lung cancer (a) (black arrow). Immunohistochemical analysis of the resected tumor revealed that the immunohistostaining…
First-line series Second-line series Unselected patients INTACT-1, INTACT-2 IDEAL 1 and 2 BR.21 Iressa Survival Evaluation in Lung Cancer V-15-32 INTEREST Selection by background IPASS Selection by EGFR mutation…
Fig. 5.1 Nodal staging using EBUS-TBNA combined with EUS-(B)-FNA. A CP-EBUS was used for EBUS-TBNA, which evaluated station 4L. The same bronchoscope was then introduced into the esophagus, and station…
Fig. 4.1 Specimens used for the EGFR mutation test in Japan. The sample categories summarized from ~17,000 samples submitted to one of the laboratories in 2009 [38]. Tissue samples (i.e.,…
